A Phase II Study of Neoadjuvant Chemoradiotherapy with Docetaxel, Cisplatin and 5-FU Followed by Surgical Resection in the Treatment of Locally Advanced Esophagogastric Junction Cancer and Locally Advanced Esophageal Cancer.
Chien-Chih ChenHui-Ling YehCheng-Yeh ChuangChung-Ping HsuPublished in: Clinics and practice (2024)
The use of the DCF regimen in neoadjuvant chemoradiotherapy followed by surgery demonstrated tolerable toxicity and achieved acceptable DFS and OS outcomes.
Keyphrases
- locally advanced
- phase ii study
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- minimally invasive
- papillary thyroid
- coronary artery bypass
- squamous cell
- randomized controlled trial
- oxidative stress
- surgical site infection
- type diabetes
- metabolic syndrome
- acute coronary syndrome
- clinical trial
- combination therapy
- skeletal muscle
- open label
- weight loss
- insulin resistance
- adipose tissue
- replacement therapy